Dr. Seibyl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
60 Temple St
Ste 8B
New Haven, CT 06510Phone+1 203-401-4300
Education & Training
Yale-New Haven Medical CenterResidency, Nuclear Medicine, 1992 - 1994- Yale-New Haven Medical CenterResidency, Psychiatry, 1986 - 1990
Greenwich Hospital/Yale UniversityResidency, Internal Medicine, 1985 - 1986
Case Western Reserve University School of MedicineClass of 1986
Certifications & Licensure
CT State Medical License 1988 - 2024- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease Start of enrollment: 2005 Jan 01
- An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) Start of enrollment: 2004 Mar 01
- Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects Start of enrollment: 2006 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 355 citationsFlorbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 studyOsama Sabri, Marwan N. Sabbagh, John Seibyl, Henryk Barthel, Hiroyasu Akatsu
Alzheimer's & Dementia. 2015-08-01 - 452 citationsCSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohortsOskar Hansson, John Seibyl, Erik Stomrud, Henrik Zetterberg, John Q. Trojanowski
Alzheimer's & Dementia. 2018-11-01 - 279 citationsThe Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, Shirley Lasch, Christopher S. Coffey
Annals of Clinical and Translational Neurology. 2018-10-31
Journal Articles
- Assessment of 18f-PI-2620 as a Biomarker in Progressive Supranuclear PalsyJohn Seibyl, MD, JAMA Neurology
Press Mentions
CWRU Alumni Give $7.5 Million to Case Western Reserve University for Research into Parkinson’s, Alzheimer’s and Multiple SclerosisJune 7th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
